Selecta Biosciences to Participate in Upcoming Investor Conferences
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company, announced CEO Carsten Brunn's participation in two upcoming virtual investor conferences in November 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company, announced CEO Carsten Brunn's participation in two upcoming virtual investor conferences in November 2020. The conferences include the Jefferies Virtual London Healthcare Conference on November 17, at 9:05 a.m. ET, and the Stifel 2020 Virtual Healthcare Conference on November 18, at 2 p.m. ET. Live webcasts will be accessible via Selecta’s website. The company focuses on developing therapies to manage immune responses using its ImmTOR™ platform, with clinical trials expected to start in early 2021.
Details
News Market Reaction – SELB
The recorded move for SELB in the trading session of this news was -0.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:
Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17, 2020
Presentation time: 9:05 a.m. ET
Stifel 2020 Virtual Healthcare Conference
Date: Wednesday, November 18, 2020
Fireside chat time: 2 p.m. ET
Live webcasts will be available in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With an observed ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in collaboration with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com
For Investors:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com
For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.